Oslo, Norway, 6 March 2017: Targovax ASA (“Targovax” or “the Company”; OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target, primarily, treatment-resistant solid tumors, announces that members of its senior management will present at the following life sciences and investor conferences:
10th European Life Science CEO Forum (hosted by Sachs Associates)
Date: 7 March 2017
Venue: Hilton Zurich Airport Hotel, Zurich, Switzerland
Panel discussion time: 11:10 CET – Advances in Immuno-Oncology Therapeutics Panel
– Magnus Jäderberg (CMO)
Presentation time: 12:25 CET
– Øystein Soug (CEO)
Redeye – Fight Cancer Seminar
Date: 10 March 2017
Venue: Redeye, Stockholm, Sweden
Presentation time: 10:50 CET
Participants: Øystein Soug (CEO)
11th Annual BIO-Equity Spring 2017 Conference
Date: 20-22 March 2017
Venue: CCIB Convention Centre in Barcelona, Spain
Participants: Øystein Soug (CEO) and Peter Skorpil (VP Business Development)
The presentations will be available to download at www.circio.com following these events.
For further information, please contact:
Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Email: renate.birkeli@targovax.com
Media and IR enquires:
Jan Petter Stiff – Crux Advisers (Norway)
Phone: +47 995 13 891
Email: stiff@crux.no
Julia Phillips/Simon Conway – FTI Consulting (International)
Phone: +44 20 3727 1000
Email: Targovax@fticonsulting.com
About Targovax
Arming the patient’s immune system to fight cancer
Targovax is a clinical stage company focused on developing and commercializing novel immuno-oncology therapies to target, primarily, treatment-resistant solid tumors. Immuno-oncology is currently one of the fastest growing therapeutic fields in medicine.
The Company’s development pipeline is based on two novel proprietary platforms:
The first platform, ONCOS, uses oncolytic viruses, an emerging class of biological therapy. ONCOS exclusively uses an adenovirus that has been engineered to be a tumor-targeted immune activator. The platform has the potential to generate therapies with superior efficacy and safety compared to the first approved oncolytic virus therapy, Imlygic®, launched by Amgen. We continue to expect key proof of concept data for this platform in 2017 from a clinical study of lead program ONCOS-102 in patients with refractory malignant melanoma.
The second platform, TG-Peptides (TGP), solely targets tumors that express mutated forms of the RAS protein. Mutations to this protein are common in many cancers and are known to drive aggressive disease progression and treatment resistance. There is a high unmet medical need for therapies that are effective against tumors that express these mutations. The TGP platform’s therapeutic potential stems from its ability to enable a patient’s immune system to identify and then destroy tumors bearing any RAS mutations. In early 2017, key proof of concept data for the TGP platform from a clinical study of TG01 in resected pancreatic cancer patients showed encouraging overall survival and will determine plans for the future clinical development of this platform.
Targovax’s development pipeline has three novel therapeutic candidates in clinical development covering six indications. Already promising safety and tolerability data and early signs of clinical response have been demonstrated.
Both platforms are protected by an extensive portfolio of IP and know-how and have the potential to yield multiple product candidates in a cost-effective manner. We have a number in early stages of development in addition to the three outlined above.
In July, 2016 the Company listed its shares on Oslo Axess.
This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.